Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671697 · ClinicalTrials.gov registry record · Phase 1
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00671697 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 13 participants.
The verdict
NCT00671697, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia
Interventions
- DRUG Decitabine
- DRUG Arsenic Trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671697
The ClinicalTrials.gov registry entry for NCT00671697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT00671697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671697 about?
NCT00671697 is a clinical study titled "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia". This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia
What is the current status of trial NCT00671697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00671697?
The interventions under investigation include: Decitabine (DRUG), Arsenic Trioxide (DRUG).
Who is sponsoring clinical trial NCT00671697?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.